• Toxicological Research
• /
• v.29 no.1
• /
• pp.1-6
• /
• 2013

The process of drug discovery and development requires substantial resources and time. The drug industry has tried to reduce costs by conducting appropriate animal studies together with molecular biological and genetic analyses. Basic science research has been limited to in vitro studies of cellular processes and ex vivo tissue examination using suitable animal models of disease. However, in the past two decades new technologies have been developed that permit the imaging of live animals using radiotracer emission, X-rays, magnetic resonance signals, fluorescence, and bioluminescence. The main objective of this review is to provide an overview of small animal molecular imaging, with a focus on nuclear imaging (single photon emission computed tomography and positron emission tomography). These technologies permit visualization of toxicodynamics as well as toxicity to specific organs by directly monitoring drug accumulation and assessing physiological and/or molecular alterations. Nuclear imaging technology has great potential for improving the efficiency of the drug development process.

• Journal of Gastric Cancer
• /
• v.14 no.1
• /
• pp.1-6
• /
• 2014

Aerobic glycolysis has been the most important hypothesis in cancer metabolism. It seems to be related to increased bioenergetic and biosynthetic needs in rapidly proliferating cancer cells. To this end, F-18 fluorodeoxyglucose (FDG), a glucose analog, became widely popular for the detection of malignancies combined with positron emission tomography/computed tomography (PET/CT). Although the potential roles of FDG PET/CT in primary tumor detection are not fully established, it seems to have a limited sensitivity in detecting early gastric cancer and mainly signet ring or non-solid types of advanced gastric cancer. In evaluating lymph node metastases, the location of lymph nodes and the degree of FDG uptake in primary tumors appear to be important factors affecting the diagnostic accuracy of PET/CT. In spite of the limited sensitivity, the high specificity of PET/CT for lymph node metastases may play an important role in changing the extent of lymphadenectomy or reducing futile laparotomies. For peritoneal metastases, PET/CT seems to have a poorer sensitivity but a better specificity than CT. The roles of PET/CT in the evaluation of other distant metastases are yet to be known. Studies including primary tumors with low FDG uptake or peritoneal recurrence seem suffer from poorer diagnostic performance for the detection of recurrent gastric cancer. There are only a few reports using FDG PET/CT to predict response to neoadjuvant or adjuvant chemotherapy. A complete metabolic response seems to be predictive of more favorable prognosis.

• Nuclear Engineering and Technology
• /
• v.56 no.6
• /
• pp.2412-2420
• /
• 2024

The International Atomic Energy Agency (IAEA) mandates safeguards to ensure non-proliferation of nuclear materials. Among inspection techniques used to detect partial defects within spent nuclear fuel (SNF), gamma emission tomography (GET) has been reported to be reliable for detection of partial defects on a pin-by-pin level. Conventional GET, however, is limited by low detection efficiency due to the high density of nuclear fuel rods and self-absorption. This paper proposes a new type of GET named Spent Fuel Internal Tomography (SFIT), which can acquire sinograms at the guide tube. The proposed device consists of the housing, shielding, C-shaped collimator, reflector, and gadolinium aluminum gallium garnet (GAGG) scintillator. For accurate attenuation correction, the source-distinguishable range of the SFIT device was determined using MC simulation to the region away from the proposed device to the second layer. For enhanced inspection accuracy, a proposed specific source-discrimination algorithm was applied. With this, the SFIT device successfully distinguished all source locations. The comparison of images of the existing and proposed inspection methods showed that the proposed method, having successfully distinguished all sources, afforded a 150 % inspection accuracy improvement.

• Brain Tumor Research and Treatment
• /
• v.6 no.2
• /
• pp.47-53
• /
• 2018

Brain tumors represent a diverse spectrum of histology, biology, prognosis, and treatment options. Although MRI remains the gold standard for morphological tumor characterization, positron emission tomography (PET) can play a critical role in evaluating disease status. This article focuses on the use of PET with radiolabeled glucose and amino acid analogs to aid in the diagnosis of tumors and differentiate between recurrent tumors and radiation necrosis. The most widely used tracer is $^{18}F$-fluorodeoxyglucose (FDG). Although the intensity of FDG uptake is clearly associated with tumor grade, the exact role of FDG PET imaging remains debatable. Additionally, high uptake of FDG in normal grey matter limits its use in some low-grade tumors that may not be visualized. Because of their potential to overcome the limitation of FDG PET of brain tumors, $^{11}C$-methionine and $^{18}F$-3,4-dihydroxyphenylalanine (FDOPA) have been proposed. Low accumulation of amino acid tracers in normal brains allows the detection of low-grade gliomas and facilitates more precise tumor delineation. These amino acid tracers have higher sensitivity and specificity for detecting brain tumors and differentiating recurrent tumors from post-therapeutic changes. FDG and amino acid tracers may be complementary, and both may be required for assessment of an individual patient. Additional tracers for brain tumor imaging are currently under development. Combinations of different tracers might provide more in-depth information about tumor characteristics, and current limitations may thus be overcome in the near future. PET with various tracers including FDG, $^{11}C$-methionine, and FDOPA has improved the management of patients with brain tumors. To evaluate the exact value of PET, however, additional prospective large sample studies are needed.

• Journal of Radiopharmaceuticals and Molecular Probes
• /
• v.7 no.2
• /
• pp.99-103
• /
• 2021

In this study, the initial in vivo pharmacokinetic changes according to the routes of drug administration were investigated using bioimaging techniques. The purpose of this study was to quantify the degree of distribution of each major organ in normal mice over time by acquiring Positron Emission Tomography/Computed Tomography images while administering routes F-18 fluorodeoxyglucose such as intravenous, intraperitoneal and per oral, a representative diagnostic radiopharmaceutical. Dynamic Positron Emission Tomography images were acquired for 90 minutes after drug administration. Radioactivity uptake was calculated for major organs using the PMOD program. In the case of intravenous administration, it was confirmed that it spread quickly and evenly to major organs. Compared to intravenous administration, intraperitoneal administration was about three times more absorbed and distributed in the liver and intestine, and it was showed that the amount excreted through the bladder was more than twice. In the case of oral administration, most stayed in the stomach, and it was showed that it spread slowly throughout the body. In comparison with intravenous administration, it was presented that the distribution of kidneys was more than 9 times and the distribution of bladder was 66% lower. Since there is a difference in the initial in vivo distribution and excretion of each administration method, we confirmed that the determination of the administration route is important for in vivo imaging evaluation of new drug candidates.

• 대한두경부종양학회:학술대회논문집
• /
• 1998.05a
• /
• pp.112-114
• /
• 1998

• The Korean Journal of Nuclear Medicine
• /
• v.31 no.3
• /
• pp.291-298
• /
• 1997

• 대한위암학회:학술대회논문집
• /
• 2004.04a
• /
• pp.34-34
• /
• 2004

• 대한치과보철학회:학술대회논문집
• /
• 1999.04a
• /
• pp.33-33
• /
• 1999

• 대한핵의학회:학술대회논문집
• /
• 1990.04a
• /
• pp.213.1-213.1
• /
• 1990